2022 World Conference on Lung Cancer (ePosters)-EP08.01-105. Efficacy of First-Line Immune Checkpoint Inhibitors in Patients with Advanced NSCLC harboring KRAS, MET, FGFR, RET, BRAF, and HER2 Alterations

EP08.01-105. Efficacy of First-Line Immune Checkpoint Inhibitors in Patients with Advanced NSCLC harboring KRAS, MET, FGFR, RET, BRAF, and HER2 Alterations

Back to course

Pdf Summary

A study conducted by Yuji Uehara, Kageaki Watanabe, and Yukio Hosomi aimed to investigate the efficacy of first-line immune checkpoint inhibitors (ICI) in patients with advanced non-small cell lung cancer (NSCLC) who had specific alterations in their tumor genes, including KRAS, MET, RET, BRAF, HER2, FGFR, and unknown alterations. The study included 78 patients who received ICI treatment as their initial therapy between May 2019 and July 2021, excluding those involved in clinical trials. The researchers identified somatic alterations in tumor tissues through targeted DNA and RNA sequencing.<br /><br />The results showed that the efficacy of ICI was favorable in patients with KRAS alterations, particularly KRAS G12C, with median progression-free survival (PFS) of 16.2 months and 26.6 months, respectively. However, patients with MET alterations had shorter median PFS of 2.8 months. In contrast, patients with RET, BRAF, HER2, and FGFR alterations did not demonstrate decreased efficacy of ICI, with median PFS of 11.7 months. The retrospective analysis had some limitations, including the heterogeneity of ICI treatments received and the inability to obtain tumor mutation burden and co-alterations.<br /><br />The study concluded that the benefit of first-line ICI treatment was similar in advanced NSCLC regardless of the specific driver alterations, except for MET alterations. However, due to the small sample size, further studies are needed to determine the benefit of ICI use in these rare patient groups. The authors provided their contact information for any inquiries. The study referenced previous research that showed conflicting results regarding the efficacy of ICI in patients with rare oncogenic drivers, emphasizing the need for more comprehensive investigations. Overall, this real-world study sheds light on the outcomes of first-line ICI therapy in NSCLC patients with specific gene alterations, providing valuable insights for future treatment approaches.

Asset Subtitle

Yuji Uehara

Meta Tag

Speaker Yuji Uehara

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

study

immune checkpoint inhibitors

non-small cell lung cancer

tumor genes

KRAS

MET

RET

BRAF

HER2

FGFR